deltatrials
Unknown PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT00448734

A Study of Picoplatin and Docetaxel in Subjects With Prostate Cancer

A Phase 1/2 Study of Picoplatin and Docetaxel (With Prednisone) in Subjects With Chemotherapy-Naive Metastatic Hormone-Refractory Prostate Cancer

Sponsor: Poniard Pharmaceuticals

Conditions Hormone Refractory Prostate Cancer
Interventions Picoplatin docetaxel
Updated 6 times since 2017 Last updated: Jan 20, 2009 Started: Jun 30, 2006 Primary completion: Dec 31, 2009 Completion: Jul 31, 2010
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Hormone Refractory Prostate Cancer and is currently ongoing. Poniard Pharmaceuticals leads this study, which shows 6 recorded versions since 2006 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotUnknown Status~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotUnknown Status~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotUnknown Status~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotUnknown~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotUnknown~Sep 2025 – present · 10 months · monthly snapshotUnknown

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Unknown PHASE1/PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Unknown PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE1/PHASE2

    Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Unknown Status PHASE1_PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Unknown Status PHASE1_PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Unknown Status PHASE1_PHASE2

    First recorded

Jun 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Poniard Pharmaceuticals
Data source: Poniard Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations